Loading...
NPI 1578223632 · Niles, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Hannan Lab Inc is a clinical medical laboratory provider located in Niles, Illinois. This profile covers 24 Medicare and 12 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Hannan Lab Inc |
| Address | 6954 W Touhy Ave Ste 201 |
| City | Niles |
| State | IL |
| ZIP | 60714 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 29, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $7.4M |
| Medicaid | $209.9K |
HANNAN LAB INC is effectively Medicare-focused by scale: it reports Total Medicare revenue of $7.4M compared with Total Medicaid revenue of $209.9K, indicating Medicare drives the bulk of its business. The Medicaid footprint exists but is small relative to Medicare and concentrated in pandemic-related testing.
The provider’s top three Medicare codes — 87798 (15.2%), 80434 (14.3%), and 87150 (13.4%) — together account for 42.9% of its total Medicare revenue, showing concentrated dependency on a small set of high-revenue services. Two of those top-three codes (87798 and 87150) are molecular/probe-based organism detection codes and 80434 is an insulin-tolerance–type metabolic evaluation, suggesting the operation mixes high-throughput molecular infectious-disease testing with at least some specialized endocrine/metabolic testing.
Medicaid revenue is highly concentrated: the top three Medicaid codes U0003 (49.8%), 87426 (21.8%), and G2023 (16.1%) make up 87.7% of the provider's total Medicaid revenue. Those three are all COVID-19–related testing or specimen-collection codes (U0003 and 87426 are nucleic-acid and antigen assays and G2023 is specimen collection), indicating the provider’s Medicaid business is dominated by pandemic-era diagnostic services.
HANNAN LAB shows dominant national volume on several high-throughput infectious-disease codes: 87636 is reported as an extreme outlier (ranks #8 of 2192), 87502 is an extreme outlier (ranks #11 of 3547), and 87426 is an extreme outlier (ranks #4 of 17750), signaling a nationally large footprint in multiplex respiratory and COVID/influenza molecular testing. At the same time, some high-revenue Medicare codes such as 87798 rank as typical/ unremarkable volume (ranks #59 of 1319, 96th percentile), so the provider’s competitive position varies by specific test.
For Medicaid-specific competitive standing within Illinois, U0003 (rank #123 of 350, 65th percentile) and G2023 (rank #114 of 396, 71st percentile) are at typical in-state volumes, while 87426 is stronger in-state (rank #71 of 910, 92nd percentile). This mix implies the lab is a modest to strong state-level performer for antigen and nucleic-acid COVID testing but not uniformly dominant across all Medicaid test types.
Several routine, low–average-paid tests show very high claim volumes consistent with reference-lab scale operations: 86905 (36.7K claims) and 87186 (18.2K claims) have large claim counts with low $/claim and are ranked as extreme outlier (86905 ranks #1 of 12) or notably above typical (87186 ranks in the 99th percentile), which is consistent with high-throughput batching and downstream processing for many specimens. Those high-volume, low-unit-revenue procedures support a business model centered on volume processing rather than high-margin individualized testing.
The provider’s NPI was enumerated on 2021-12-29 (~5 years ago), indicating relatively recent entry to the datasets, yet it has scaled quickly in several national test categories. Rapid scaling to be an extreme outlier on multiple high-throughput molecular codes within a few years suggests investment in automated or high-throughput testing capacity.
Operationally, the mix of high-throughput respiratory molecular codes (87636, 87502, U0004/U0005/U0003) alongside specialized services such as hemoglobin fractionation 83020 (rank #1 of 232, extreme outlier) and metabolic testing 80434 (rank #1 of 1 nationally) indicates a hybrid lab strategy: dominant volume-based infectious-disease diagnostics plus capacity for niche or specialized assays. Analysts should interpret this as a lab with both broad reference-lab throughput and select specialized testing capabilities rather than a narrow single-test facility.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
24 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 33,200 | $30 | $1.1M |
| 80434 | The lab analyst measures the glucose and cortisol levels in each of five blood samples, one taken before and four taken after the administration of insulin. | 3,810 | $280 | $1.1M |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 29,270 | $30 | $995.1K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 5,310 | $140 | $743.5K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 6,420 | $70 | $475.4K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 12,770 | $30 | $434.2K |
| 80155 | A lab tests a patient's specimen to determine the level of caffeine. | 10,170 | $40 | $386.5K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 3,410 | $90 | $320.2K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 11,740 | $20 | $269.9K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 6,430 | $40 | $224.9K |
Showing 1–10 of 24
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 24 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
24 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 80434 | 1 | 10 | 3,810 | $280 | $1.1M |
| 80155 | 1 | 10 | 10,170 | $40 | $384.4K |
| U0004 | 4 | 20 | 530 | $70 | $383.5K |
| 87150 | 1 | 10 | 1,200 | $30 | $181.3K |
| 87798 | 4 | 70 | 750 | $30 | $172.3K |
| 86905 | 1 | 10 | 36,680 | $1 | $137.7K |
| G2023 | 6 | 90 | 400 | $20 | $96.5K |
| U0005 | 11 | 100 | 270 | $20 | $86.3K |
| 82652 | 1 | 10 | 1,390 | $40 | $69.6K |
| 87636 | 3 | 120 | 30 | $140 | $50K |
Showing 1–10 of 24
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
12 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1,430 | $70 | $104.7K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 1,430 | $30 | $45.9K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1,610 | $20 | $33.9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 1,170 | $20 | $25.8K |
| 80434 | The lab analyst measures the glucose and cortisol levels in each of five blood samples, one taken before and four taken after the administration of insulin. | 20 | $10 | $110 |
| 86905 | The lab analyst performs a test to type, or identifies the patient’s blood group according to an antigen, other than ABO or RhD antigens, present on the surface of red blood cells, or RBCs. He uses… | 10 | $1 | $30 |
| 80155 | A lab tests a patient's specimen to determine the level of caffeine. | 20 | $0 | $0 |
| 83020 | The lab analyst records and calculates the hemoglobin fractions in a whole blood sample demonstrated by this hemoglobin fractionation test by electrophoresis. | 10 | $0 | $0 |
| 87086 | Culture, bacterial; quantitative, colony count, urine. | 30 | $0 | $0 |
| 87088 | The lab analyst or microbiologist observes a urine culture with an unknown organism or organisms and makes a presumptive identification of each organism that needs identification. | 30 | $0 | $0 |
Showing 1–10 of 12
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
12 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 39 | 50 | 710 | $70 | $1.2M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 123 | 350 | 400 | $70 | $514.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 89 | 210 | 680 | $20 | $206.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 114 | 400 | 550 | $20 | $90.8K |
| 87086 | Culture, bacterial; quantitative, colony count, urine. | 312 | 340 | 1,030 | $10 | $36.4K |
| 87088 | The lab analyst or microbiologist observes a urine culture with an unknown organism or organisms and makes a presumptive identification of each organism that needs identification. | 152 | 180 | 500 | $10 | $30.3K |
| 87186 | The lab analyst performs the technical steps to evaluate a culture isolate’s susceptibility, or sensitivity, to multiple antimicrobial agents, commonly called antibiotics, by observing growth of the… | 220 | 240 | 790 | $10 | $19.4K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 71 | 910 | 110 | $30 | $14.4K |
| 83020 | The lab analyst records and calculates the hemoglobin fractions in a whole blood sample demonstrated by this hemoglobin fractionation test by electrophoresis. | 59 | 60 | 280 | $10 | $9.6K |
| 86905 | The lab analyst performs a test to type, or identifies the patient’s blood group according to an antigen, other than ABO or RhD antigens, present on the surface of red blood cells, or RBCs. He uses… | 6 | 10 | 100 | $1 | $410 |
Showing 1–10 of 12
Other providers in the same ZIP code as Hannan Lab Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| American Scientific Laboratory Inc | IL | Clinical Medical Laboratory | $482.2K | $24M |
| Ace Medical Supply LLC | IL | Durable Medical Equipment & Medical Supplies | $0 | $10.3M |
| Village Of Niles | IL | Land Ambulance | $595.4K | $8.3M |
| Kingsway Home Health Services,inc | IL | Home Health Agency | $0 | $7.3M |
| Spectrum Lab Corp | IL | Clinical Medical Laboratory | $4.8M | $44.6K |
| Rumya Rao | IL | Retina Specialist (Ophthalmology) Physician | $1.7M | $2M |
| Matthew Wessel | IL | Retina Specialist (Ophthalmology) Physician | $2.3M | $1.3M |
| Asian Human Services Family Health Center, Inc | IL | Federally Qualified Health Center (FQHC) | $0 | $3.4M |
| John Eklund | IL | Hematology & Oncology Physician | $1.3M | $8.4K |
| Care One Pharmacy Services LLC | IL | Long Term Care Pharmacy | $262.5K | $856.9K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.